Nexalin Technology Inc. (NXL)
| Bid | 0.96 |
| Market Cap | 16.14M |
| Revenue (ttm) | 168.72K |
| Net Income (ttm) | -7.61M |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | -1.46 |
| Forward PE | -3.74 |
| Analyst | Buy |
| Ask | 1.57 |
| Volume | 153,207 |
| Avg. Volume (20D) | 156,258 |
| Open | 1.33 |
| Previous Close | 1.33 |
| Day's Range | 1.21 - 1.33 |
| 52-Week Range | 0.53 - 4.49 |
| Beta | 4.73 |
About NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various m...
Analyst Forecast
According to 1 analyst ratings, the average rating for NXL stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 312.88% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 year ago · proactiveinvestors.com
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransNexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury...
